Condition: Advanced Solid Tumor · Sponsor: Vall d'Hebron Institute of Oncology
The global objective of this Basket of Basket study is to evaluate the antitumor activity of each matched therapies that will be evaluated through the study in small molecularly selected populations. The objective of module 1 wil be to determine the overall response rate (ORR) at 12 weeks by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 of atezolizumab in each of the arms of the module. All patients in genomically selected populations will receive atezolizumab 1200 mg IV every 3 weeks. The objective of module 2 wil be to determine the overall response rate (ORR) at 16 weeks by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 of futibatinib in each of the arms of the module. All patients in genomically selected populations will receive will receive futibatinib, 20 mg, once daily (QD) in 28-day cycles. The objective of module 3 wil be to determine the overall response rate (ORR) at 12 weeks by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 of amivantamab in each of the arms of the module. All patients in genomically selected populations will receive amivantamab 1050 mg intravenously (IV) for body weight \< 80 kg and 1400 mg for body weight \>= 80 kg mg once weekly in Cycle 1 (with a split dose on Days 1-2) and then every 2 weeks in subsequent cycles (28-day cycles).
This description comes directly from the study's public registry record.
Marta Carboneras · +34 686 187 838 · mcarboneras@vhio.net
Susana Muñoz · +34 934 893 000 · smunoz@vhio.net
Always discuss trial participation with your own doctor first.
| Institut Gustave Roussy | Villejuif, France | Recruiting |
| Deutsches Krebsforschungszentrum (NCT/DKFZ) | Heidelberg, Baden-Wurttemberg, Germany | Recruiting |
| Universitätsklinikum Dresden | Dresden, Germany | Recruiting |
| Instituto Nazionale dei Tumori di Milano | Milan, Italy | Recruiting |
| Nederland Kanker Instituut (NKI) | Amsterdam, Netherlands | Recruiting |
| Hospital Vall d'Hebron | Barcelona, Spain | Recruiting |
| Karolinska University Hospital Solna | Stockholm, Sweden | Recruiting |
| Cancer Research UK Cambridge Centre | Cambridge, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03767075